oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2016-15-5-65-72oncotomsk-408Research ArticleОБЗОРЫREVIEWSМОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ МАРКЕРЫ ОПУХОЛЕВОГО ОТВЕТА ПРИ НЕОАДЪЮВАНТНОЙ ХИМИОЛУЧЕВОЙ ТЕРАПИИ РАКА ПРЯМОЙ КИШКИMOLECULAR GENETIC MARKERS AS PREDICTORS OF TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR RECTAL CANCERАлтыбаевС. Р.AltybaevS. R.

аспирант кафедры патологической анатомии, Сибирский государственный медицинский университет (г. Томск, Российская Федерация)

Postgraduate, Pathological Anatomy Department, Siberian State Medical University (Tomsk, Russian Federation)

selver_altibaev@mail.ruАфанасьевС. Г.AfanasyevS. G.

доктор медицинских наук, профессор, главный научный сотрудник торако-абдоминального отделения, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Российская Федерация)

MD, DSc, Professor, Chief Researcher, Thoracic and Abdominal Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russian Federation)

AfanasievSG@oncology.tomsk.ruЗавьяловаМ. В.ZavyalovaM. V.

доктор медицинских наук, профессор, заведующая кафедрой патологической анатомии, Сибирский государственный медицинский университет (г. Томск, Российская Федерация)

MD, DSc, Professor, Head of Pathological Anatomy Department, Siberian State Medical University (Tomsk, Russian Federation)

zavyalovamv@mail.ruСтепановИ. В.StepanovI. V.

кандидат медицинских наук, доцент кафедры патологической анатомии, Сибирский государственный медицинский университет (г. Томск, Российская Федерация)

MD, PhD, Assistant Professor, Pathological Anatomy Department, Siberian State Medical University (Tomsk, Russian Federation)

ivanstepanov@sibmail.comСорокинД. А.SorokinD. A.

аспирант торако-абдоминального отделения, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Российская Федерация)

Postgraduate, Thoracic and Abdominal Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russian Federation)

Dmitrii1110@mail.ruФГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава России, г. Томск 634009, г. Томск, Московский тракт, 2РоссияSiberian State Medical University, Russia, Tomsk 2, Moskovsky Tract, 634009-Tomsk, RussiaRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. ТомскРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russia, TomskRussian FederationФГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава России, г. Томск 634009, г. Томск, Московский тракт, 2 Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. ТомскРоссияSiberian State Medical University, Russia, Tomsk 2, Moskovsky Tract, 634009-Tomsk, Russia Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russia, TomskRussian FederationФГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава России, г. Томск 634009, г. Томск, Московский тракт, 2РоссияSiberian State Medical University, Russia, Tomsk 2, Moskovsky Tract, 634009-Tomsk, Russia Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russia, TomskRussian Federation2016181120161556572Copyright © Алтыбаев С.Р., Афанасьев С.Г., Завьялова М.В., Степанов И.В., Сорокин Д.А., 20162016Алтыбаев С.Р., Афанасьев С.Г., Завьялова М.В., Степанов И.В., Сорокин Д.А.Altybaev S.R., Afanasyev S.G., Zavyalova M.V., Stepanov I.V., Sorokin D.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/408

В обзоре представлены пути и механизмы воздействия на биологические свойства опухолевых клеток рака прямой кишки (РПК). Описаны эффекты проводимой неоадъювантной химиолучевой терапии по поводу РПК, а также дана характеристика пролиферативной активности, апоптоза, межклеточной адгезии, миграции опухолевых клеток РПК под влиянием комбинированной терапии. Приведена характеристика молекулярно-генетических маркеров, их связь с химио- и радиочувствительностью, а также прогностическая значимость при РПК.

The review presents the mechanisms involved in the biological behavior of rectal cancer cells. The tumor response to neoadjuvant chemoradiotherapy was evaluated. The characteristics of proliferative activity, apoptosis, cell adhesion, and migration of rectal cancer cells influenced by chemotherapy were described. The relationship between molecular genetic markers and prediction of response to chemoradiation in rectal cancer was shown.

рак прямой кишкинеоадъювантная химиолучевая терапияопухолевый ответиммуногистохимическиегенетические маркерыrectal cancerneoadjuvant chemoradiationtumor responseimmunohistochemistrygenetic markersReferencesBrenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet. 2014 Apr 26; 383 (9927): 1490–502. doi: 10.1016/S0140-6736(13)61649-9.Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet. 2014 Apr 26; 383 (9927): 1490–502. doi: 10.1016/S0140-6736(13)61649-9.Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9–29. doi: 10.3322/caac.21208.Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9–29. doi: 10.3322/caac.21208.Злокачественные новообразования в России в 2013 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России; 2015, 250 с.Cancer in Russia in 2013 (incidence and mortality) / Ed. by А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. М.: P.A. Gertsen Moscow Research Oncology Institute; 2015, 250 p. [in Russian]Афанасьев С.Г., Старцева Ж.А., Тарасова А.С., Усова А.В., Самцов Е.Н. Результаты комбинированного лечения рака прямой кишки с применением пролонгированной предоперационной химиолучевой терапии. Сибирский онкологический журнал; 2012. № 6: 5–12.Afanasyev S.G., Startseva Zh.А., Tarasova А.S., Usova А.V., Samtsov Е.N. Results of combined modality treatment including preoperative plolonged chemotherary for rectal cancer. Siberian Journal of Oncology. 2012. 6: 5–12. [in Russian]Барсуков Ю.А., Ткачев С.И., Власов О.А., Николаев А.В. Неоадъювантная крупнофракционная лучевая терапия в комбинированном лечении рака прямой кишки. Вестник РОНЦ им. Н.Н. Блохина РАМН. 1999; Т. 10, № 2: 41–48.Barsukov Yu.A., Tkachev S.I., Vlasov O.А., Nikolaev АV. Neoadjuvant large fraction radiotherapy in the multimodality treatment of rectal cancer. Herald of N.N. Blokhin Russian Cancer Research Center. 1999; 10 (2): 41–48. [in Russian]Правосудов И.В., Алиев И.И., Шулепов А.В., Крживицкий П.И. Мультидисциплинарный подход к лечению больных раком прямой кишки: оценка клинического и патологического ответа у больных, получавших предоперационную химиолучевую терапию. Онкологическая колопроктология. 2012; 1: 7–11.Pravosudov I.V., Aliev I.I., Shulepov A.V., Krzhivitskiy P.I. Multidisciplinary approach to the treatment of patients with rectal cancer: assessment of clinical and pathologic response to preoperative chemoradiotherapy. Onkologicheskaja koloproktologija. 2012; 1: 7–11. [in Russian]Барсуков Ю.А., Ткачев С.И., Кузьмичев Д.В., Мамедли З.З., Павлова А.М. Комплексное лечение больных операбельным раком прямой кишки дистальной локализации. Онкологическая колопроктология. 2012; 3: 28–38.Barsukov Yu.A., Tkachev S.I., Kuzmichev D.V., Mamedli Z.Z., Pavlova А.М. Comprehensive treatment of patients with operable rectal cancer. Onkologicheskaja koloproktologija. 2012; 3: 28–38.Appelt A.L., Plоen J., Harling H., Jensen F.S., Jensen L.H., Jоrgensen J.C., Lindebjerg J., Rafaelsen S.R., Jakobsen A. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015; 16 (8): 919–27. doi: 10.1016/S1470-2045(15)00120-5.Appelt A.L., Plоen J., Harling H., Jensen F.S., Jensen L.H., Jоrgensen J.C., Lindebjerg J., Rafaelsen S.R., Jakobsen A. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015; 16 (8): 919–27. doi: 10.1016/S1470-2045(15)00120-5.Kim S.H., Chang H.J., Kim D.Y., Park J.W., Baek J.Y., Kim S.Y., Park S.C., Oh J.H., Yu A., Nam B.H. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016 Jul; 48 (3): 998–1009. doi: 10.4143/crt.2015.254.Kim S.H., Chang H.J., Kim D.Y., Park J.W., Baek J.Y., Kim S.Y., Park S.C., Oh J.H., Yu A., Nam B.H. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016 Jul; 48 (3): 998–1009. doi: 10.4143/crt.2015.254.Kwok H., Bissett I.P., Hill G.L. Preoperative staging of rectal cancer. Int J Colorectal Dis. 2000 Feb; 15 (1): 9–20.Kwok H., Bissett I.P., Hill G.L. Preoperative staging of rectal cancer. Int J Colorectal Dis. 2000 Feb; 15 (1): 9–20.Gerdes J., Schwab U., Lemke H., Stein H. Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15; 31 (1): 13–20.Gerdes J., Schwab U., Lemke H., Stein H. Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15; 31 (1): 13–20.Willett C.G., Warland G., Cheek R., Coen J., Efird J., Shellito P.C., Compton C.C. Proliferating Cell Nuclear Antigen and Mitotic Activity in Rectal Cancer: Predictor of Response to Preoperative Irradiation. J. Clin. Oncol. 1994; Vol. 12 (4): 679–682.Willett C.G., Warland G., Cheek R., Coen J., Efird J., Shellito P.C., Compton C.C. Proliferating Cell Nuclear Antigen and Mitotic Activity in Rectal Cancer: Predictor of Response to Preoperative Irradiation. J. Clin. Oncol. 1994; Vol. 12 (4): 679–682.Jakob C., Liersch T., Meyer W., Becker H., Baretton G.B., Aust D.E. Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol. 2008; 14 (7): 1060–6.Jakob C., Liersch T., Meyer W., Becker H., Baretton G.B., Aust D.E. Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU- based chemoradiotherapy. World J Gastroenterol. 2008; 14 (7): 1060–6.Kazem A., Sayed K.El., Kerm Y.El. Prognostic significance of COX-2 and b-catenin in colorectal carcinoma. Alexandria Journal of Medicine. 2014 Sep; 50 (3): 211–220.Kazem A., Sayed K.El., Kerm Y.El. Prognostic significance of COX-2 and b-catenin in colorectal carcinoma. Alexandria Journal of Medicine. 2014 Sep; 50 (3): 211–220.Cai G., Zhang Z., Zhu J., Gu W., Zhang S., Hu Y., Li G., Cai S. The Role of COX-2 Expression in locally advanced rectal cancer treated with neoadjuvant concurrent radiation with capecitabine/oxaliplatin and celecoxib. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75 (3): S261.Cai G., Zhang Z., Zhu J., Gu W., Zhang S., Hu Y., Li G., Cai S. The Role of COX- 2 Expression in locally advanced rectal cancer treated with neoadjuvant concurrent radiation with capecitabine/oxaliplatin and celecoxib. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75 (3): S261.Shinto E., Hashiguchi Y., Ueno H., Kobayashi H., Ishiguro M., Mochizuki H., Yamamoto J., Hase K. Pretreatment CD133 and cyclooxygenase- 2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum. 2011 Sep; 54 (9): 1098–106. doi: 10.1097/DCR.0b013e3182218155.Shinto E., Hashiguchi Y., Ueno H., Kobayashi H., Ishiguro M., Mochizuki H., Yamamoto J., Hase K. Pretreatment CD133 and cyclooxygenase- 2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum. 2011 Sep; 54 (9): 1098–106. doi: 10.1097/DCR.0b013e3182218155.Kim Y., Kim H., Kim N., Shin S.J., Keum K. Molecular markers aid prediction of treatment failure after surgical resection and adjuvant chemoradiation for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012 Nov; 84 (3): S350.Kim Y., Kim H., Kim N., Shin S.J., Keum K. Molecular markers aid prediction of treatment failure after surgical resection and adjuvant chemoradiation for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012 Nov; 84 (3): S350.Chen M.B., Wu X.Y., Yu R., Li C., Wang L.Q., Shen W., Lu P.H. P53 Status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One. 2012; 7 (9): e45388. doi: 10.1371/journal.pone.0045388.Chen M.B., Wu X.Y., Yu R., Li C., Wang L.Q., Shen W., Lu P.H. P53 Status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One. 2012; 7 (9): e45388. doi: 10.1371/journal.pone.0045388.Sakai K., Kazama S., Nagai Y., Murono K., Tanaka T., Ishihara S., Sunami E., Tomida S., Nishio K., Watanabe T. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget. 2014 Oct 30; 5 (20): 9641–9.Sakai K., Kazama S., Nagai Y., Murono K., Tanaka T., Ishihara S., Sunami E., Tomida S., Nishio K., Watanabe T. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget. 2014 Oct 30; 5 (20): 9641–9.Andrade N.R., Fujiyama C.T. Gomes T.S., Neto R.A., Forones N.M. Imunoexpression of Ki- 67 and p53 in rectal cancer tissue after treatment with neoadjuvant. Chemoradiation J Gastrointest Cancer. 2011 Mar; 42 (1): 34–9. doi: 10.1007/s12029-010-9225-1.Andrade N.R., Fujiyama C.T. Gomes T.S., Neto R.A., Forones N.M. Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant. Chemoradiation J Gastrointest Cancer. 2011 Mar; 42 (1): 34–9. doi: 10.1007/s12029010-9225-1.Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993 Nov 19; 75 (4): 805–16.Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk- interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993 Nov 19; 75 (4): 805–16.Roninson I.B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002; 179 (1): 1–14.Roninson I.B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002; 179 (1): 1–14.Sturm I., Rau B., Schlag P.M., Wust P., Hildebrandt B., Riess H., Hauptmann S., Dörken B., Daniel P.T. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer. 2006 May 10; 6: 124.Sturm I., Rau B., Schlag P.M., Wust P., Hildebrandt B., Riess H., Hauptmann S., Dörken B., Daniel P.T. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer. 2006 May 10; 6: 124.Sim S.H., Kang M.H., Kim Y.J., Lee K.W., Kim D.W., Kang S.B., Eom K.Y., Kim J.S., Lee H.S., Kim J.H. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer. 2014; 14: 241. doi: 10.1186/1471-2407-14-241.Sim S.H., Kang M.H., Kim Y.J., Lee K.W., Kim D.W., Kang S.B., Eom K.Y., Kim J.S., Lee H.S., Kim J.H. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer. 2014; 14: 241. doi: 10.1186/1471-2407-14-241.Oliva J.L., Griner E.M., Kazanietz M.G. PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors. Growth Factors. 2005 Dec; 23 (4): 245–52.Oliva J.L., Griner E.M., Kazanietz M.G. PKC isozymes and diacylglycerol- regulated proteins as effectors of growth factor receptors. Growth Factors. 2005 Dec; 23 (4): 245–52.Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005 Dec; 4 (12): 988–1004.Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005 Dec; 4 (12): 988–1004.Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30 (1): 91–8.Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30 (1): 91–8.Kim J.S., Kim J.M., Li S., Yoon W.H., Song K.S., Kim K.H., Yeo S.G., Nam J.S., Cho M.J. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patient treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 1; 66 (1): 195–200.Kim J.S., Kim J.M., Li S., Yoon W.H., Song K.S., Kim K.H., Yeo S.G., Nam J.S., Cho M.J. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patient treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 1; 66 (1): 195–200.Toiyama Y., Inoue Y., Saigusa S., Okugawa Y., Yokoe T., Tanaka K., Miki C., Kusunoki M. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol). 2010 May; 22 (4): 272–80. doi: 10.1016/j.clon.2010.01.001.Toiyama Y., Inoue Y., Saigusa S., Okugawa Y., Yokoe T., Tanaka K., Miki C., Kusunoki M. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol). 2010 May; 22 (4): 272–80. doi: 10.1016/j.clon.2010.01.001.Giralt J., de las Heras M., Cerezo L., Eraso A., Hermosilla E., Velez D., Lujan J., Espin E., Rosello J., Majó J., Benavente S., Armengol M., de Torres I.; Grupo Español de Investigacion Clinica en Oncologia Radioterápica (GICOR). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol. 2005 Feb; 74 (2): 101–8.Giralt J., de las Heras M., Cerezo L., Eraso A., Hermosilla E., Velez D., Lujan J., Espin E., Rosello J., Majó J., Benavente S., Armengol M., de Torres I.; Grupo Español de Investigacion Clinica en Oncologia Radioterápica (GICOR). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol. 2005 Feb; 74 (2): 101–8.Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010 Feb; 10 (2): 116–29. doi: 10.1038/nrc2780.Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010 Feb; 10 (2): 116–29. doi: 10.1038/nrc2780.Tian Y.F., Chen T.J., Lin C.Y., Chen L.T., Lin L.C., Hsing C.H., Lee S.W., Sheu M.J., Lee H.H., Shiue Y.L., Huang H.Y., Pan H.Y., Li C.F., Chen S.H. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents at herapeutic target with high potential. Tumour Biol. 2013 Apr; 34 (2): 1107–17. doi: 10.1007/s13277-013-0652-z.Tian Y.F., Chen T.J., Lin C.Y., Chen L.T., Lin L.C., Hsing C.H., Lee S.W., Sheu M.J., Lee H.H., Shiue Y.L., Huang H.Y., Pan H.Y., Li C.F., Chen S.H. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents at herapeutic target with high potential. Tumour Biol. 2013 Apr; 34 (2): 1107–17. doi:10.1007/s13277-013-0652-z.Li C.F., He H.L., Wang J.Y., Huang H.Y., Wu T.F., Hsing C.H., Lee S.W., Lee H.H., Fang J.L., Huang W.T., Chen S.H. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec; 67 (12): 1056–61. doi: 10.1136/jclinpath-2014-202551.Li C.F., He H.L., Wang J.Y., Huang H.Y., Wu T.F., Hsing C.H., Lee S.W., Lee H.H., Fang J.L., Huang W.T., Chen S.H. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec; 67 (12): 1056–61. doi: 10.1136/jclinpath-2014-202551.García-Solano J., Conesa-Zamora P., Trujillo-Santos J., Torres-Moreno D., Mäkinen M.J., Pérez-Guillermo M. Immunohistochemical expression profile of β-catenin, E-cadherin, P- cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum Pathol. 2012 Jul; 43 (7): 1094–102. doi: 10.1016/j.humpath.2011.08.020.García-Solano J., Conesa-Zamora P., Trujillo-Santos J., Torres-Moreno D., Mäkinen M.J., Pérez-Guillermo M. Immunohistochemical expression profile of β- catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum Pathol. 2012 Jul; 43 (7): 1094–102. doi: 10.1016/j.humpath.2011.08.020.Kawada K., Taketo M.M. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res. 2011. Feb 15; 71 (4): 1214–8. doi: 10.1158/0008-5472.CAN-10- 3277.Kawada K., Taketo M.M. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res. 2011. Feb 15; 71 (4): 1214–8. doi: 10.1158/00085472.CAN-10-3277.Bhangu A., Wood G., Brown G., Darzi A., Tekkis P., Goldin R. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. Colorectal Dis. 2014 Apr; 16 (4): O133–43. doi: 10.1111/codi.12482.Bhangu A., Wood G., Brown G., Darzi A., Tekkis P., Goldin R. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. Colorectal Dis. 2014 Apr; 16 (4): O133–43. doi: 10.1111/codi.12482.Wang L., Zhang X.M., Li Z., Liu X.J., Chai J., Zhang G.Y., Cheng Y.F. Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance. World J Gastroenterol. 2013 Oct 28; 19 (40): 6876–82. doi: 10.3748/wjg.v19.i40.6876.Wang L., Zhang X.M., Li Z., Liu X.J., Chai J., Zhang G.Y., Cheng Y.F. Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance. World J Gastroenterol. 2013 Oct 28; 19 (40): 6876–82. doi: 10.3748/wjg.v19.i40.6876.Gomez-Millan J., Jobacho A.R., Gil M.D., Villa L.P., de Luque V., Garrido S.R., Perez J.R., Perez S., Rios I.G., Serrano M.T., Lozano E.B., Carmona J.M. Neoadjuvant radiochemotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: Prognostic significance. Rep Pract Oncol Radiother. 2013 Jun; 18 (1). S116–S117.Gomez-Millan J., Jobacho A.R., Gil M.D., Villa L.P., de Luque V., Garrido S.R., Perez J.R., Perez S., Rios I.G., Serrano M.T., Lozano E.B., Carmona J.M. Neoadjuvant radiochemotherapy in rectal cancer induces changes in the expression of nuclear β- catenin: Prognostic significance. Rep Pract Oncol Radiother. 2013 Jun; 18 (1). S116– S117.Rahman L., Voeller D., Rahman M., Lipkowitz S., Allegra C., Barrett J.C., Kaye F.J., Zajac- Kaye M. Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004; 5 (4): 341–351.Rahman L., Voeller D., Rahman M., Lipkowitz S., Allegra C., Barrett J.C., Kaye F.J., Zajac-Kaye M. Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004; 5 (4): 341–351.Unger K.R., Romney D.A., Koc M., Moskaluk C.A., Friel C.M., Foley E.F., Rich T.A. Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys. 2011 Aug 1; 80 (5): 1377–82. doi: 10.1016/j.ijrobp.2010.04.016.Unger K.R., Romney D.A., Koc M., Moskaluk C.A., Friel C.M., Foley E.F., Rich T.A. Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys. 2011 Aug 1; 80 (5): 1377–82. doi: 10.1016/j.ijrobp.2010.04.016.Páez D., Salazar J., Paré L., Pertriz L., Targarona E., del Rio E., Barnadas A., Marcuello E., Baiget M. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81 (5): 1319–27. doi: 10.1016/j.ijrobp.2011.01.025.Páez D., Salazar J., Paré L., Pertriz L., Targarona E., del Rio E., Barnadas A., Marcuello E., Baiget M. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81 (5): 1319–27. doi: 10.1016/j.ijrobp.2011.01.025.Roninson I.B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002; 179 (1): 1–14.Roninson I.B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002; 179 (1): 1–14.Lamas M.J., Duran G., Gomez A., Balboa E., Anido U., Bernardez B., Rana-Diez P., Lopez R., Carracedo A., Barros F. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82 (1): 138–44. doi: 10.1016/j.ijrobp.2010.09.053.Lamas M.J., Duran G., Gomez A., Balboa E., Anido U., Bernardez B., Rana-Diez P., Lopez R., Carracedo A., Barros F. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82 (1): 138–44. doi: 10.1016/j.ijrobp.2010.09.053.Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., Zhang J., Ratajczak J., Ratajczak M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004 Mar; 35 (3): 233–45.Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., Zhang J., Ratajczak J., Ratajczak M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004 Mar; 35 (3): 233–45.Casado E., García V.M., Sánchez J.J., Blanco M., Maurel J., Feliu J., Fernández-Martos C., de Castro J., Castelo B., Belda-Iniesta C., Sereno M., Sánchez-Llamas B., Burgos E., García- Cabezas M.Á., Manceñido N., Miquel R., García-Olmo D., González-Barón M., Cejas P. A combined strategy of SAGE and quantitative PCR provides a 13-Gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res. 2011; 17 (12): 4145–54. doi: 10.1158/1078-0432.CCR-10-2257.Casado E., García V.M., Sánchez J.J., Blanco M., Maurel J., Feliu J., Fernández- Martos C., de Castro J., Castelo B., Belda-Iniesta C., Sereno M., Sánchez-Llamas B., Burgos E., García-Cabezas M.Á., Manceñido N., Miquel R., García-Olmo D., González- Barón M., Cejas P. A combined strategy of SAGE and quantitative PCR provides a 13- Gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res. 2011; 17 (12): 4145–54. doi: 10.1158/1078-0432. CCR- 10-2257.Saigusa S., Toiyama Y., Tanaka K., Yokoe T., Okugawa Y., Kawamoto A., Yasuda H., Inoue Y., Miki C., Kusunoki M. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 2010 Aug; 17 (8): 2051–8. doi: 10.1245/s10434-010-0970-y.Saigusa S., Toiyama Y., Tanaka K., Yokoe T., Okugawa Y., Kawamoto A., Yasuda H., Inoue Y., Miki C., Kusunoki M. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 2010 Aug; 17 (8): 2051–8. doi: 10.1245/s10434-010-0970-y.Li C., Wang Z., Liu F., Zhu J., Yang L., Cai G., Zhang Z., Huang W., Cai S., Xu Y. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol. 2014 Oct; 35 (10): 9683–91. doi: 10.1007/s13277-014-2234-0.Li C., Wang Z., Liu F., Zhu J., Yang L., Cai G., Zhang Z., Huang W., Cai S., Xu Y. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol. 2014 Oct; 35 (10): 9683–91. doi: 10.1007/s13277-014-2234-0.D’Alterio C., Avallone A., Tatangelo F., Delrio P., Pecori B., Cella L., Pelella A., D’Armiento F.P., Carlomagno C., Bianco F., Silvestro L.,Pacelli R., Napolitano M., Iaffaioli R.V., Scala S. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. Int J Cancer. 2014 Jul 15; 135 (2): 379–90. doi: 10.1002/ijc.28689.D’Alterio C., Avallone A., Tatangelo F., Delrio P., Pecori B., Cella L., Pelella A., D’Armiento F.P., Carlomagno C., Bianco F., Silvestro L., Pacelli R., Napolitano M., Iaffaioli R.V., Scala S. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. Int J Cancer. 2014 Jul 15; 135 (2): 379–90. doi: 10.1002/ijc.28689.Yamamoto H., Adachi Y., Taniguchi H., Kunimoto H., Nosho K., Suzuki H., Shinomura Y. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 2012 Jun 14; 18 (22): 2745–55. doi: 10.3748/wjg.v18.i22.2745.Yamamoto H., Adachi Y., Taniguchi H., Kunimoto H., Nosho K., Suzuki H., Shinomura Y. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 2012 Jun 14; 18 (22): 2745–55. doi: 10.3748/wjg.v18.i22.2745.de la Chapelle A. Microsatellite instability. N. Engl. J. Med. 2003; 349 (3): 209–210.de la Chapelle A. Microsatellite instability. N. Engl. J. Med. 2003; 349 (3): 209–210.Du C., Zhao J., Xue W., Dou1 F., Gu J. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology. 2013; 62 (5): 723–30. doi: 10.1111/his.12069.Du C., Zhao J., Xue W., Dou1 F., Gu J. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology. 2013; 62 (5): 723–30. doi: 10.1111/his.12069.Yang L., Sun Y., Huang X.E., Yu D.S., Zhou J.N., Zhou X., Li D.Z., Guan X. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer. Asian Pac. J. Cancer Prev. 2015; 16 (4): 1545–51.Yang L., Sun Y., Huang X.E., Yu D.S., Zhou J.N., Zhou X., Li D.Z., Guan X. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer. Asian Pac. J. Cancer Prev. 2015; 16 (4): 1545–51.Demes M., Scheil-Bertram S., Bartsch H., Fisseler-Eckhoff A. Signature of microsatellite instability: KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. J Gastrointest Oncol. 2013 Jun; 4 (2): 182–92. doi: 10.3978/j.issn.2078-6891.2013.012.Demes M., Scheil-Bertram S., Bartsch H., Fisseler-Eckhoff A. Signature of microsatellite instability: KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. J Gastrointest Oncol. 2013 Jun; 4 (2): 182–92. doi: 10.3978/j.issn.2078-6891.2013.012.Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010 Mar 1; 28 (7): 1254-61. doi: 10.1200/JCO.2009.24.6116.Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010 Mar 1; 28 (7): 1254-61. doi: 10.1200/JCO.2009.24.6116.Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F., Schilsky R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27 (12): 2091–6. doi: 10.1200/JCO.2009.21.9170.Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F., Schilsky R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27 (12): 2091–6. doi: 10.1200/JCO.2009.21.9170.Lee J.W., Lee J.H., Shim B.Y., Kim S.H., Chung M.J., Kye B.H., Kim H.J., Cho H.M., Jang H.S. KRAS mutation status is not a predictor for tumor response and survival in rectal cancer patients who received preoperative radiotherapy with 5-fluoropyrimidine followed by curative surgery. Medicine (Baltimore). 2015 Aug; 94 (31): e1284. doi: 10.1097/MD.0000000000001284.Lee J.W., Lee J.H., Shim B.Y., Kim S.H., Chung M.J., Kye B.H., Kim H.J., Cho H.M., Jang H.S. KRAS mutation status is not a predictor for tumor response and survival in rectal cancer patients who received preoperative radiotherapy with 5- fluoropyrimidine followed by curative surgery. Medicine (Baltimore). 2015 Aug; 94 (31): e1284. doi: 10.1097/MD.0000000000001284.Gaedcke J., Grade M., Jung K., Schirmer M., Jo P., Obermeyer C., Wolff H.A., Herrmann M.K., Beissbarth T., Becker H., Ried T., Ghadimi M. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010 Jan; 94 (1): 76–81. doi: 10.1016/j.radonc.2009.10.001.Gaedcke J., Grade M., Jung K., Schirmer M., Jo P., Obermeyer C., Wolff H.A., Herrmann M.K., Beissbarth T., Becker H., Ried T., Ghadimi M. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010 Jan; 94 (1): 76–81. doi: 10.1016/j.radonc.2009.10.001.Martellucci J., G. Alemanno, Castiglione F., Bergamini C., Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015 Mar; 67 (1): 47–53. doi: 10.1007/s13304-015-0281-8.Martellucci J., G. Alemanno, Castiglione F., Bergamini C., Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015 Mar; 67 (1): 47–53. doi: 10.1007/s13304-015-0281-8.Garassino M.C., Marabese M., Rusconi P., Rulli E., Martelli O., Farina1 G., Scanni A., Broggini M. Different types of KRas mutations could affect drug sensitivity and tumour behavior in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22 (1): 235–7. doi: 10.1093/annonc/mdq680.Garassino M.C., Marabese M., Rusconi P., Rulli E., Martelli O., Farina1 G., Scanni A., Broggini M. Different types of KRas mutations could affect drug sensitivity and tumour behavior in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22 (1): 235–7. doi: 10.1093/annonc/mdq680.

The authors declare that there are no conflicts of interest present.